American Biotechnology Laboratory Titles Modern They appreciated more than 10% after the opening of Wall Street, after the company announced that the Data Security Monitoring Board (DSMB), independently appointed by the National Institutes of Health of the United States (NIH, for its acronym in English), reported that the phase 3 study of mRNA-1273, its vaccine candidate against covid-19, has observed an efficacy of 94.5% in the first analyzes.
Specific, Moderna’s shares have risen 12.4% in the first moments of trading on the Nasdaq, up to a maximum of $ 100.50. However, after the first minutes of the session on Monday, the titles of the biotechnology laboratory moderated their rise to 8.74%, at 97.20 dollars.
So far this year, the shares of companies in the pharmaceutical sector have increased fivefold in value at the prospect of finding an effective vaccine against covid-19, from $ 19.56 at the end of 2019 to more than $ 100 that you have reached at the opening of the session.
On his side, the actions of Pfizer, which last Monday celebrated with similar euphoria the progress of the vaccine against covid-19 that it develops together with BioNTech, they left 3.29% of their price on Monday, while the value of the certificates of deposit (ADR) of BioNTech shares lost 9.96%.
Based on the provisional safety and efficacy data registered, Moderna advanced this Monday in a statement that it “intends” to request an emergency use authorization to the US Food and Drug Administration (FDA) in “the next few weeks” and anticipates that authorization will be marked by final safety and efficacy data (with an average duration of at least 2 months ). Moderna also assures that “it plans to submit applications for authorization to global regulatory bodies.”
20 million doses
Moderna has reported that by the end of 2020 it expects to have approximately 20 million doses ready to be shipped to the US. In the same way, they affirm that they “are still on the way” to manufacture between 500 million and 1 billion doses worldwide in 2021.
Furthermore, the company has announced that its vaccine remains stable at a temperature of 2 ° to 8 ° C, the temperature of a standard home or refrigerator, for 30 days. In addition, they ensure that it remains stable at -20ºC for up to six months for storage and at room temperature for up to 12 hours.